Edwards Lifesciences Raises Full Year Outlook After 1Q Beat

Dow Jones04-24 04:46

By Christopher Kuo

Edwards Lifesciences raised its full-year outlook after earnings and revenue topped Wall Street forecasts.

The medical technology company on Thursday raised its full-year forecast for sales to $6.5 to $6.9 billion and the expected midpoint of its adjusted earnings per share to $2.95 to $3.05. Analysts polled by FactSet project revenue of $6.68 billion and adjusted earnings of $2.97 a share.

For the second quarter, the company projects sales of $1.66 to $1.74 billion, and adjusted earnings of 70 cents a share to 76 cents a share. Analysts project revenue of $1.68 billion and adjusted earnings of 75 cents.

The company reported a profit of $380.7 million, or 66 cents a share, compared with $358 million, or 61 cents a share, a year earlier.

Adjusted earnings per share were 78 cents a share, above analysts' expectations of 73 cents a share, according to FactSet.

Revenue rose to $1.65 billion from $1.41 billion a year earlier. Analysts were expecting revenue of $1.6 billion.

The company's revenue growth was driven by transcatheter aortic valve replacement sales, which rose 14% to $1.2 billion. Surgical sales rose 10% to $276.2 million.

Write to Christopher Kuo at chris.kuo@wsj.com

(END) Dow Jones Newswires

April 23, 2026 16:46 ET (20:46 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629865144?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 04:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629865144","market":"fut","top_or_hot":-1,"title":"Edwards Lifesciences Raises Full Year Outlook After 1Q Beat","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Edwards Lifesciences raised its full-year outlook after earnings and revenue topped Wall Street forecasts. \n</p>\n<p>\n  The medical technology company on Thursday raised its full-year forecast for sales to $6.5 to $6.9 billion and the expected midpoint of its adjusted earnings per share to $2.95 to $3.05. Analysts polled by FactSet project revenue of $6.68 billion and adjusted earnings of $2.97 a share. \n</p>\n<p>\n  For the second quarter, the company projects sales of $1.66 to $1.74 billion, and adjusted earnings of 70 cents a share to 76 cents a share. Analysts project revenue of $1.68 billion and adjusted earnings of 75 cents. \n</p>\n<p>\n  The company reported a profit of $380.7 million, or 66 cents a share, compared with $358 million, or 61 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings per share were 78 cents a share, above analysts' expectations of 73 cents a share, according to FactSet. \n</p>\n<p>\n  Revenue rose to $1.65 billion from $1.41 billion a year earlier. Analysts were expecting revenue of $1.6 billion. \n</p>\n<p>\n  The company's revenue growth was driven by transcatheter aortic valve replacement sales, which rose 14% to $1.2 billion. Surgical sales rose 10% to $276.2 million. \n</p>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 23, 2026 16:46 ET (20:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edwards Lifesciences Raises Full Year Outlook After 1Q Beat</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdwards Lifesciences Raises Full Year Outlook After 1Q Beat\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-24 04:46</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Christopher Kuo \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Edwards Lifesciences raised its full-year outlook after earnings and revenue topped Wall Street forecasts. \n</p>\n<p>\n  The medical technology company on Thursday raised its full-year forecast for sales to $6.5 to $6.9 billion and the expected midpoint of its adjusted earnings per share to $2.95 to $3.05. Analysts polled by FactSet project revenue of $6.68 billion and adjusted earnings of $2.97 a share. \n</p>\n<p>\n  For the second quarter, the company projects sales of $1.66 to $1.74 billion, and adjusted earnings of 70 cents a share to 76 cents a share. Analysts project revenue of $1.68 billion and adjusted earnings of 75 cents. \n</p>\n<p>\n  The company reported a profit of $380.7 million, or 66 cents a share, compared with $358 million, or 61 cents a share, a year earlier. \n</p>\n<p>\n  Adjusted earnings per share were 78 cents a share, above analysts' expectations of 73 cents a share, according to FactSet. \n</p>\n<p>\n  Revenue rose to $1.65 billion from $1.41 billion a year earlier. Analysts were expecting revenue of $1.6 billion. \n</p>\n<p>\n  The company's revenue growth was driven by transcatheter aortic valve replacement sales, which rose 14% to $1.2 billion. Surgical sales rose 10% to $276.2 million. \n</p>\n<p>\n  Write to Christopher Kuo at chris.kuo@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 23, 2026 16:46 ET (20:46 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BN0W2W23.USD","symbol_name":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2629865144","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2629865144","pubTimestamp":1776977160,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Edwards Lifesciences raised its full-year outlook after earnings and revenue topped Wall Street forecasts.The medical technology company on Thursday raised its full-year forecast for sales to $6.5 to $6.9 billion and the expected midpoint of its adjusted earnings per share to $2.95 to $3.05. Analysts polled by FactSet project revenue of $6.68 billion and adjusted earnings of $2.97 a share.For the second quarter, the company projects sales of $1.66 to $1.74 billion, and adjusted earnings of 70 cents a share to 76 cents a share. Analysts project revenue of $1.68 billion and adjusted earnings of 75 cents.The company reported a profit of $380.7 million, or 66 cents a share, compared with $358 million, or 61 cents a share, a year earlier.Adjusted earnings per share were 78 cents a share, above analysts' expectations of 73 cents a share, according to FactSet.Revenue rose to $1.65 billion from $1.41 billion a year earlier. Analysts were expecting revenue of $1.6 billion.The company's revenue ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","EW":"爱德华兹","LU0345774391.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) ACC","BK4504":"桥水持仓","IE00BYQQ9H92.USD":"BNY MELLON GLOBAL LEADERS \"A\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK4567":"ESG概念","SG9999001176.USD":"United Global Healthcare Acc USD","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00BFXG0V08.USD":"BNY MELLON GLOBAL LEADERS \"B\" (USD) ACC","BK4082":"医疗保健设备"},"translate_title":"爱德华兹生命科学公司在第一季度表现良好后上调全年预期","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1.5},"content_text":"By Christopher Kuo \n\n\n \n\n\n  Edwards Lifesciences raised its full-year outlook after earnings and revenue topped Wall Street forecasts. \n\n\n  The medical technology company on Thursday raised its full-year forecast for sales to $6.5 to $6.9 billion and the expected midpoint of its adjusted earnings per share to $2.95 to $3.05. Analysts polled by FactSet project revenue of $6.68 billion and adjusted earnings of $2.97 a share. \n\n\n  For the second quarter, the company projects sales of $1.66 to $1.74 billion, and adjusted earnings of 70 cents a share to 76 cents a share. Analysts project revenue of $1.68 billion and adjusted earnings of 75 cents. \n\n\n  The company reported a profit of $380.7 million, or 66 cents a share, compared with $358 million, or 61 cents a share, a year earlier. \n\n\n  Adjusted earnings per share were 78 cents a share, above analysts' expectations of 73 cents a share, according to FactSet. \n\n\n  Revenue rose to $1.65 billion from $1.41 billion a year earlier. Analysts were expecting revenue of $1.6 billion. \n\n\n  The company's revenue growth was driven by transcatheter aortic valve replacement sales, which rose 14% to $1.2 billion. Surgical sales rose 10% to $276.2 million. \n\n\n  Write to Christopher Kuo at chris.kuo@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 23, 2026 16:46 ET (20:46 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629865144","isCrawlerRequest":true}